Beijing, China – September 2, 2025 – Pulmongene Ltd., a leading clinical-stage biotechnology company focused on discovering and developing innovative therapies for respiratory disorders and fibrotic diseases, today announced that its Phase 1b clinical trial data for PMG1015 have been selected for a presentation as a Late-Breaking-Abstract at the European Respiratory Society (ERS) International Congress 2025 in Amsterdam, Netherlands. The conference will be held from September 27 to October 1, 2025.
The presentation, titled “PMG1015 Demonstrates Well-Tolerated Safety and Favorable FVC Changes After 12 Weeks of Treatment in IPF Patients”, will be presented in the poster presentation session on September 30th, 2025, by Dr. Toby Maher. Late-breaking abstracts are reserved by ERS for studies deemed to have significant clinical or scientific impact, underscoring the novelty and potential of PMG1015 in addressing critical unmet needs in pulmonary fibrosis treatment.
“We are honored that ERS has recognized the importance of our PMG1015 Phase 1b data as late-breaking science,” said Nan Tang, Founder of Pulmongene Ltd. “These results represent a critical step forward in validating PMG1015’s potential to transform treatment for IPF. We look forward to sharing our findings with the global respiratory community and advancing PMG1015 into later-stage clinical development.”